Análise de custo-utilidade do colírio latanoprosteno bunode no tratamento do glaucoma primário de ângulo aberto sob a perspectiva do Sistema Único de Saúde
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Glaucoma is a progressive optic neuropathy that impairs visual function and quality of
life, and is the leading cause of irreversible blindness worldwide. The Brazilian Unified
Health System (Sistema Único de Saúde – SUS) guarantees universal access to
pharmacological, surgical, and laser treatments for the disease, offering these services
free of charge as part of its public health policy. New pharmacological therapies have
become available on the market, such as latanoprostene bunod (LBN) 0.024% eye
drops, which have demonstrated greater efficacy in reducing intraocular pressure
compared to latanoprost. However, LBN has not yet been assessed for incorporation
into the Brazilian health system. This study aims to assess the incremental cost-utility
ratio (ICUR) of LBN 0.024% as a first-line treatment for primary open-angle glaucoma
(POAG), compared to the current standard recommended by the Clinical Protocol and
Therapeutic Guidelines (PCDT) of SUS. A cost‑utility analysis was conducted using a
hypothetical cohort and a Markov model. The budgetary perspective adopted was that
of the Brazilian Unified Health System (SUS), with a time horizon beginning at age 60
and extending to the average life expectancy of the Brazilian population. In the base‑
case scenario, we adopted the strategy recommended by the PCDT for glaucoma,
assuming initiation of treatment with timolol 0.05%. In the event of failure to reach the
target intraocular pressure, dorzolamide 2% and a prostaglandin analogue were added
sequentially. The comparator scenario considered using LBN 0.024% eye drops as the
first therapeutic option, followed by combinations of timolol 0.05% and dorzolamide 2%
as needed. After model simulation, the incremental cost‑utility ratio (ICUR) was
BRL 31,244.98 per QALY for the strategy starting with LBN 0.024%, compared with
the SUS strategy. Entry age (40 or 70 years) in the model was the parameter that had
the greatest impact on the ICUR, resulting in costs of BRL 24,953.82 and BRL
50,284.30 per QALY, respectively. Based on the recommended cost‑effectiveness
threshold of up to one GDP per capita (gross domestic product per capita, GDP), which
is BRL 55,247.45 for 2024 according to the Brazilian Institute of Geography and
Statistics, we conclude that the incorporation of LBN 0.024% as a first‑line medication
in the clinical treatment of primary open‑angle glaucoma is cost‑effective from the SUS
perspective.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

